Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 5, 2013, Pages 494-506

  Zhang, Yi Hong ^a   Raymick, James ^b   Sarkar, Sumit ^a   Lahiri, Debomoy K ^d   Ray, Balmiki ^d   Holtzman, David ^e   Dumas, Melanie ^c   Schmued, Larry C ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b Toxicologic Pathology Associates   (United States)

^c Priority One   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid plaque; Amyloid beta42; Astrocytes; Clioquinol; Myelinopathy; Transgenic mice; Vaccine

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CLIOQUINOL; VACCINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL HYPERPLASIA; CONTROLLED STUDY; DRUG EFFICACY; ENCEPHALITIS; FEMALE; IMMUNOHISTOCHEMISTRY; INOCULATION; LATERAL GENICULATE BODY; LATERAL SEPTAL NUCLEUS; MALE; MOUSE; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; SEPTUM NUCLEUS; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIPSYCHOTIC AGENTS; CLIOQUINOL; DISEASE MODELS, ANIMAL; ENCEPHALITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENICULATE BODIES; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, TRANSGENIC; MUTATION; MYELIN SHEATH; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1; VACCINATION;

EID: 84885900082     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310050005     Document Type: Article

References (81)

1. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17: 489-517 (1994).
2. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 16: 5795-5811 (1996).
3. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400: 173-177 (1999).
4. St George-Hyslop PH, Westaway DA. Alzheimer's disease. Antibody clears senile plaques. Nature 400: 116-117 (1999).
5. Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 7: 1181-1183 (2004).
6. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 10 Suppl: S2-9 (2004).
7. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523-527 (1995).
8. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102 (1996).
9. Bareggi SR, Cornelli U. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neu-rosci Ther 18: 41-46 (2012).
10. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676 (2001).
11. Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5: 535-551 (2004).
12. Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT. Novel drug targets based on metallobiology of Alzheimer's disease. Expert Opin Ther Targets 14: 1177-1197 (2010).
13. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52 (1998).
14. Lee JY, Mook-Jung I, Koh JY. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci 19: RC10 (1999).
15. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94: 9866-9868 (1997).
16. Ray B, Lahiri DK. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 9: 434-444 (2009).
17. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 88: 10540-10543 (1991).
18. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70: 2212-2215 (1998).
19. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, et al. Cu(II) potentiation of alzheimer abeta neurotox-icity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274: 37111-37116 (1999).
20. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 277: 40302-40308 (2002).
21. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhy-droxyquin (clioquinol) targeting Abeta amyloid deposition and tox-icity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neu-rol 60: 1685-1691 (2003).
22. Barcia E, Salama A, Fernandez-Carballido A, Negro S. Protective effects of clioquinol on human neuronal-like cells: a new formulation of clioquinol-loaded PLGA microspheres for Alzheimer's disease. J Drug Target 19: 637-646 (2011).
23. Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacob-son LH, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31: 9323-9331 (2011).
24. Trouche SG, Asuni A, Rouland S, Wisniewski T, Frangione B, Verdier JM, et al. Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine 27: 957-964 (2009).
25. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 58: 430-435 (2005).
26. Sigurdsson EM, Wisniewski T, Frangione B. A safer vaccine for Alzheimer's disease? Neurobiol Aging 23: 1001-1008 (2002).
27. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neuro-biol Dis 15: 11-20 (2004).
28. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, et al. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation 3: 11 (2006).
29. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23: 3745-3751 (2003).
30. Minami SS, Sidahmed E, Aid S, Shimoji M, Niikura T, Mocchetti I, et al. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Abeta/amyloid burden in a trans-genic mouse model of Alzheimer's disease. J Neuroinflammation 7: 57 (2010).
31. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24: 6144-6151 (2004).
32. Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 165: 987-995 (2004).
33. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919 (2000).
34. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 20 Suppl: S20-24 (2000).
35. Sobue I, Mukoyama M, Takayanagi T, Nishigaki S, Matsuoka Y. Myeloneuropathy with abdominal disorders in Japan. Neuropa-thologic findings in seven autopsied cases. Neurology 22: 1034-1039 (1972).
36. Shiraki H. The neuropathology of subacute myelo-optico-neuropathy, SMON, in the humans: --with special reference to the quinoform intoxication. Jpn J Med Sci Biol 28 Suppl: 101-164 (1975).
37. Mumenthaler M, Kaeser HE, Meyer A, Hess T. Transient global amnesia after clioquinol: five personal observations from outside Japan. J Neurol Neurosurg Psychiatry 42: 1084-1090 (1979).
38. Kaeser HE. Transient global amnesia due to clioquinol. Acta Neu-rol Scand Suppl 100: 175-183 (1984).
39. Schaumburg HH, Spencer PS. Clioquinol. In (Eds: Spencer PS,Schaumburg HH). Experimental and Clinical Neurotoxicology. Baltimore: Williams & Wilkins pp. 395-406 (1980).
40. Tateishi J, Otsuki S. Experimental reproduction of SMON in animals by prolonged administration of clioquinol: clinico-pathological findings. Jpn J Med Sci Biol 28 Suppl: 165-186 (1975).
41. Thomas PK, Bradley DJ, Bradley WA, Degen PH, Krinke G, Muddle J, et al. Correlated nerve conduction, somatosensory evoked potential and neuropathological studies in clioquinol and 2,5-hexanedione neurotoxicity in the baboon. J Neurol Sci 64: 277-295 (1984).
42. Ismail T, Mauerhofer E, Slomianka L. The hippocampal region of rats and mice after a single i.p. dose of clioquinol: loss of synaptic zinc, cell death and c-Fos induction. Neuroscience 157: 697-707 (2008).
43. Mao X, Schimmer AD. The toxicology of Clioquinol. Toxicol Lett 182: 1-6 (2008).
44. Birmingham K, Frantz S. Set back to Alzheimer vaccine studies. Nat Med 8: 199-200 (2002).
45. Bishop GM, Robinson SR, Smith MA, Perry G, Atwood CS. Call for Elan to publish Alzheimer's trial details. Nature 416: 677 (2002).
46. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 415: 462 (2002).
47. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20 (2004).
48. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452 (2003).
49. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9: 453-457 (2003).
50. Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immuno-therapy. J Neurosci 31: 4124-4136 (2011).
51. Schmued L, Raymick J, Tolleson W, Sarkar S, Zhang YH, Bell-Cohn A. Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer especially suited for multiple labeling and large scale quantification studies. J Neurosci Methods (2012).
52. Schmued L, Bowyer J, Cozart M, Heard D, Binienda Z, Paule M. Introducing Black-Gold II, a highly soluble gold phosphate complex with several unique advantages for the histochemical localization of myelin. Brain Res 1229: 210-217 (2008).
53. Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Abeta and increases sAPPalpha levels, which parallel elevated syn-aptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6: e21954 (2011).
54. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehen-berger O, Steinberg D. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci U S A 92: 9580-9584 (1995).
55. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci U S A 93: 14833-14838 (1996).
56. Rabinowitz SS, Gordon S. Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli. J Exp Med 174: 827-836 (1991).
57. Schmued L, Raymick B, Paule M, Sarkar S. Characterization of myelin pathology in the hippocampal complex of a transgenic mouse model of Alzheimer's Disease: A Black-Gold II study. Society for Neuroscience, 2011; Washington, DC. (2011).
58. Escartin C, Bonvento G. Targeted activation of astrocytes: a potential neuroprotective strategy. Mol Neurobiol 38: 231-241 (2008).
59. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 119: 7-35 (2010).
60. Sampson EL, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Coch-rane Database Syst Rev 5: CD005380 (2012).
61. Kotaki H, Nakajima K, Tanimura Y, Saitoh Y, Nakagawa F, Ta-mura Z, et al. Appearance of intoxication in rats by intraperitoneal administration of clioquinol. J Pharmacobiodyn 6: 773-783 (1983).
62. Ozawa K, Saida K, Saida T. Experimental clioquinol intoxication in rats: abnormalities in optic nerves and small nerve cells of dorsal root ganglia. Acta Neuropathol 69: 272-277 (1986).
63. Casadesus G, Atwood CS, Zhu X, Hartzler AW, Webber KM, Perry G, et al. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. Cell Mol Life Sci 62: 293-298 (2005).
64. Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocri-nol 30: 239-258 (2009).
65. Mani ST, Thakur MK. In the cerebral cortex of female and male mice, amyloid precursor protein (APP) promoter methylation is higher in females and differentially regulated by sex steroids. Brain Res 1067: 43-47 (2006).
66. Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alz-heimer disease pathology. Arch Gen Psychiatry 62: 685-691 (2005).
67. Musicco M. Gender differences in the occurrence of Alzheimer's disease. Funct Neurol 24: 89-92 (2009).
68. Lista S, Emanuele E. Role of amyloid beta1-42 and neuroimaging biomarkers in Alzheimer's disease. Biomark Med 5: 411-413 (2011).
69. Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8: 312-336 (2012).
70. Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, et al. Change in plasma Ass peptides and onset of dementia in adults with Down syndrome. Neurology 75: 1639-1644 (2010).
71. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66: 190-199 (2009).
72. Kofler J, Lopresti B, Janssen C, Trichel AM, Masliah E, Finn OJ, et al. Preventive immunization of aged and juvenile non-human primates to beta-amyloid. J Neuroinflammation 9: 84 (2012).
73. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11: 597-604 (2012).
74. Pihlaja R, Koistinaho J, Malm T, Sikkila H, Vainio S, Koistinaho M. Transplanted astrocytes internalize deposited beta-amyloid pep-tides in a transgenic mouse model of Alzheimer's disease. Glia 56: 154-163 (2008).
75. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 20: 570-577 (1997).
76. Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxy-genases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy 4: 335-340 (2005).
77. Rothwell NJ, Hopkins SJ. Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci 18: 130-136 (1995).
78. Neary JT, Rathbone MP, Cattabeni F, Abbracchio MP, Burnstock G. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci 19: 13-18 (1996).
79. Chen Y, Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab 23: 137-149 (2003).
80. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 785: 195-206 (1998).
81. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neu-ropharmacol 33: 67-73 (2010).